Date printed: 12/12/2018
Boostrix-IPV
Details for Boostrix-IPV vaccine and its components.
Sponsor:
GlaxoSmithKline Australia
Administration route:
Intramuscular injection
Vaccine group:
Combination vaccines
Registered as a booster in people aged ≥4 years.
dTpa-IPV — diphtheria-tetanus-acellular pertussis-inactivated poliovirus combination vaccine (reduced antigen formulation)
Each 0.5 mL monodose pre-filled syringe contains:
- ≥2 IU diphtheria toxoid
- ≥20 IU tetanus toxoid
- 8 µg pertussis toxoid
- 8 µg filamentous haemagglutinin
- 2.5 µg pertactin
- 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
- 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
- 32 D-antigen units inactivated poliovirus type 3 (Saukett)
Adsorbed onto 0.5 mg aluminium as aluminium hydroxide and aluminium phosphate.
Also contains traces of:
- formaldehyde
- polysorbate 80
- polymyxin
- neomycin
The product information and consumer medicine information for Boostrix-IPV have more details.
Audience:
Infants and children
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
Definitions
- dTpa
- diphtheria-tetanus-acellular pertussis vaccine, reduced antigen content formulation
- IPV
- inactivated poliomyelitis vaccine
- IU
- international units
This document was printed on: 14/12/2018. Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/boostrix-ipv.